Structural stability of neoangiogenic intramyocardial microvessels supports functional recovery in chronic ischemic myocardium

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 1, 2008, Pages 70-80

  Shim, Winston S N ^a,b   Lim, Sze Yun ^a   Li, Shi Qi ^a   Gu, Yacui ^a   Ong, Hwee Choo ^a   Song, In Chin ^c   Chuah, Seng Chye ^a   Wong, Philip ^a  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Ischemia; Myocardial contractility; Vascular adaptation; Vascular stability

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA CATENIN; CADHERIN; MICROSPHERE; VASCULOTROPIN; VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DOPPLER ECHOCARDIOGRAPHY; FLUORESCENCE ANALYSIS; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART PERFUSION; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; SWINE; SYSTOLE;

ADENOVIRIDAE; ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD; ARTERIOLES; BETA CATENIN; CADHERINS; CHRONIC DISEASE; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY, DOPPLER; ENDOTHELIUM; FEMALE; GENE THERAPY; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RECOVERY OF FUNCTION; SWINE; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; SUIDAE;

EID: 45549095216     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.04.007     Document Type: Article

References (34)

1. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107 (2003) 1359-1365
2. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105 (2002) 788-793
3. Kastrup J., Jorgensen E., Ruck A., Tagil K., Glogar D., Ruzyllo W., et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 45 (2005) 982-988
4. Gyongyosi M., Khorsand A., Zamini S., Sperker W., Strehblow C., Kastrup J., et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112 (2005) I157-I165
5. Hedman M., Hartikainen J., Syvanne M., Stjernvall J., Hedman A., Kivela A., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 (2003) 2677-2683
6. Stewart D.J., Hilton J.D., Arnold J.M., Gregoire J., Rivard A., Archer S.L., et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 13 (2006) 1503-1511
7. Lobov I.B., Brooks P.C., and Lang R.A. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99 (2002) 11205-11210
8. Yamauchi A., Ito Y., Morikawa M., Kobune M., Huang J., Sasaki K., et al. Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model. J Gene Med 5 (2003) 994-1004
9. Uemura A., Ogawa M., Hirashima M., Fujiwara T., Koyama S., Takagi H., et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 110 (2002) 1619-1628
10. Cho C.H., Sung H.K., Kim K.T., Cheon H.G., Oh G.T., Hong H.J., et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc Natl Acad Sci U S A 103 (2006) 4946-4951
11. Lee K.W., Lip G.Y., and Blann A.D. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 110 (2004) 2355-2360
12. Shim W.S., Li W., Zhang L., Li S., Ong H.C., Song I.C., et al. Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model. J Biomed Sci 13 (2006) 579-591
13. Shim W.S., Teh M., Bapna A., Kim I., Koh G.Y., Mack P.O., et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 279 (2002) 299-309
14. Ye L., Haider H., Jiang S., Ge R., Law P.K., and Sim E.K. High efficiency transduction of human VEGF165 into human skeletal myoblasts: in vitro studies. Exp Mol Med 35 (2003) 412-420
15. Vogt F., Stein A., Rettemeier G., Krott N., Hoffmann R., vom Dahl J., et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25 (2004) 1330-1340
16. Peirce S.M., Price R.J., and Skalak T.C. Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. Am J Physiol Heart Circ Physiol 286 (2004) H918-H925
17. Clark R.B., Bouchard R.A., and Giles W.R. Action potential duration modulates calcium influx, Na(+)-Ca2+ exchange, and intracellular calcium release in rat ventricular myocytes. Ann N Y Acad Sci 779 (1996) 417-429
18. Chong A.Y., Caine G.J., Freestone B., Blann A.D., and Lip G.Y. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 43 (2004) 423-428
19. Hao X., Silva E.A., Mansson-Broberg A., Grinnemo K.H., Siddiqui A.J., Dellgren G., et al. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 75 (2007) 178-185
20. Westerhof N., Boer C., Lamberts R.R., and Sipkema P. Cross-talk between cardiac muscle and coronary vasculature. Physiol Rev 86 (2006) 1263-1308
21. Goto M., Flynn A.E., Doucette J.W., Jansen C.M., Stork M.M., Coggins D.L., et al. Cardiac contraction affects deep myocardial vessels predominantly. Am J Physiol 261 (1991) H1417-H1429
22. Kajiya F., Yada T., Matsumoto T., Goto M., and Ogasawara Y. Intramyocardial influences on blood flow distributions in the myocardial wall. Ann Biomed Eng 28 (2000) 897-902
23. Parker J.D., Landzberg J.S., Bittl J.A., Mirsky I., and Colucci W.S. Effects of beta-adrenergic stimulation with dobutamine on isovolumic relaxation in the normal and failing human left ventricle. Circulation 84 (1991) 1040-1048
24. De Bruyne B., Bronzwaer J.G., Heyndrickx G.R., and Paulus W.J. Comparative effects of ischemia and hypoxemia on left ventricular systolic and diastolic function in humans. Circulation 88 (1993) 461-471
25. Varma N., Morgan J.P., and Apstein C.S. Mechanisms underlying ischemic diastolic dysfunction: relation between rigor, calcium homeostasis, and relaxation rate. Am J Physiol Heart Circ Physiol 284 (2003) H758-H771
26. Xian Tao L., Dyachenko V., Zuzarte M., Putzke C., Preisig-Muller R., Isenberg G., et al. The stretch-activated potassium channel TREK-1 in rat cardiac ventricular muscle. Cardiovasc Res 69 (2006) 86-97
27. Tavi P., Han C., and Weckstrom M. Mechanisms of stretch-induced changes in [Ca2+]i in rat atrial myocytes: role of increased troponin C affinity and stretch-activated ion channels. Circ Res 83 (1998) 1165-1177
28. Wang H., Grant J.E., Doede C.M., Sadayappan S., Robbins J., and Walker J.W. PKC-betaII sensitizes cardiac myofilaments to Ca2+ by phosphorylating troponin I on threonine-144. J Mol Cell Cardiol 41 (2006) 823-833
29. Chilian W.M. Coronary microcirculation in health and disease. Summary of an NHLBI workshop. Circulation 95 (1997) 522-528
30. Davis S., Papadopoulos N., Aldrich T.H., Maisonpierre P.C., Huang T., Kovac L., et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10 (2003) 38-44
31. Carlson T.R., Feng Y., Maisonpierre P.C., Mrksich M., and Morla A.O. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 276 (2001) 26516-26525
32. Miao H., Hu Y.L., Shiu Y.T., Yuan S., Zhao Y., Kaunas R., et al. Effects of flow patterns on the localization and expression of VE-cadherin at vascular endothelial cell junctions: in vivo and in vitro investigations. J Vasc Res 42 (2005) 77-89
33. Zhao J., Yang Y., You S., Cui C., and Gao R. Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Int J Cardiol 115 (2007) 334-341
34. Reiss Y., Droste J., Heil M., Tribulova S., Schmidt M.H., Schaper W., et al. Angiopoietin-2 impairs revascularization after limb ischemia. Circ Res 101 (2007) 88-96